Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to -$4.2 million.

  • Q32 Bio's Cash from Operations rose 7833.21% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year increase of 4210.47%. This contributed to the annual value of -$67.7 million for FY2024, which is 26255.82% down from last year.
  • Q32 Bio's Cash from Operations amounted to -$4.2 million in Q3 2025, which was up 7833.21% from -$10.7 million recorded in Q2 2025.
  • Over the past 5 years, Q32 Bio's Cash from Operations peaked at $15.9 million during Q3 2023, and registered a low of -$30.8 million during Q2 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$19.5 million (2024), whereas its average is -$17.7 million.
  • As far as peak fluctuations go, Q32 Bio's Cash from Operations skyrocketed by 16377.75% in 2023, and later plummeted by 22277.22% in 2024.
  • Q32 Bio's Cash from Operations (Quarter) stood at -$30.4 million in 2021, then grew by 10.62% to -$27.2 million in 2022, then soared by 60.61% to -$10.7 million in 2023, then decreased by 6.65% to -$11.4 million in 2024, then surged by 62.99% to -$4.2 million in 2025.
  • Its Cash from Operations stands at -$4.2 million for Q3 2025, versus -$10.7 million for Q2 2025 and -$12.5 million for Q1 2025.